Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.
about
An Organometallic Inhibitor for the Human Repair Enzyme 7,8-Dihydro-8-oxoguanosine TriphosphataseNon-ATP-Mimetic Organometallic Protein Kinase InhibitorChemical Swarming: Depending on Concentration, an Amphiphilic Ruthenium Polypyridyl Complex Induces Cell Death via Two Different MechanismsHydrogen bonding and anticancer properties of water-soluble chiral p-cymene Ru(II) compounds with amino-oxime ligandsSynthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexesIn vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancerInfluence of the diamine on the reactivity of thiosulfonato ruthenium complexes with hydrosulfide (HS-).Heteroleptic mononuclear compounds of ruthenium(ii): synthesis, structural analyses, in vitro antitumor activity and in vivo toxicity on zebrafish embryos.Aquaporins: important but elusive drug targets.Metal complexes as potential modulators of inflammatory and autoimmune responses.Ruthenium-conjugated chrysin analogues modulate platelet activity, thrombus formation and haemostasis with enhanced efficacyGold ion-angiotensin peptide interaction by mass spectrometry.Nitro/nitrosyl-ruthenium complexes are potent and selective anti-Trypanosoma cruzi agents causing autophagy and necrotic parasite deathInteraction of a ruthenium hexacationic prism with amino acids and biological ligands: ESI mass spectrometry and NMR characterisation of the reaction products.Aquaporins as diagnostic and therapeutic targets in cancer: how far we are?Anticancer Activity of Self-Assembled Molecular Rectangles via Arene-Ruthenium Acceptors and a New Unsymmetrical Amide LigandIn vitro effects of novel ruthenium complexes in Neospora caninum and Toxoplasma gondii tachyzoites.Luminescent iminophosphorane gold, palladium and platinum complexes as potential anticancer agents.Dual mode of cell death upon the photo-irradiation of a RuII polypyridyl complex in interphase or mitosis.Potential anticancer heterometallic Fe-Au and Fe-Pd agents: initial mechanistic insights.Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action.Dicarba-closo-dodecarborane-containing half-sandwich complexes of ruthenium, osmium, rhodium and iridium: biological relevance and synthetic strategies.Anticancer metallodrug research analytically painting the "omics" picture--current developments and future trends.Metallomics insights into the programmed cell death induced by metal-based anticancer compounds.Benzyl-substituted metallocarbene antibiotics and anticancer drugs.Combination of ICP-MS, capillary electrophoresis, and their hyphenation for probing Ru(III) metallodrug-DNA interactions.Rhodium complexes as therapeutic agents.Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology?Pyrithione-based ruthenium complexes as inhibitors of aldo-keto reductase 1C enzymes and anticancer agents.The contrasting catalytic efficiency and cancer cell antiproliferative activity of stereoselective organoruthenium transfer hydrogenation catalysts.Cytotoxicity and preliminary mode of action studies of novel 2-aryl-4-thiopyrone-based organometallics.Self-assembled supramolecular hetero-bimetallacycles for anticancer potency by intracellular release.Structural characterization and biological evaluation of a clioquinol-ruthenium complex with copper-independent antileukaemic activity.Anticancer potency studies of coordination driven self-assembled arene–Ru-based metalla-bowls.Gold(I) biscarbene complexes derived from vascular-disrupting combretastatin A-4 address different targets and show antimetastatic potential.A bis(dipyridophenazine)(2-(2-pyridyl)pyrimidine-4-carboxylic acid)ruthenium(II) complex with anticancer action upon photodeprotection.Novel heterobimetallic radiotheranostic: preparation, activity, and biodistribution.Mitochondrial fragmentation is an important cellular event induced by ruthenium(II) polypyridyl complexes in osteosarcoma cells.Mitochondria are the primary target in the induction of apoptosis by chiral ruthenium(II) polypyridyl complexes in cancer cells.Ruthenium-Arene-β-Carboline Complexes as Potent Inhibitors of Cyclin-Dependent Kinase 1: Synthesis, Characterization and Anticancer Mechanism Studies.
P2860
Q27680660-65692FDF-F8E5-44BA-B45C-365E295038C4Q27681838-DD9ABB88-BDB2-467A-AA28-E71249E7039DQ28822145-5A645609-E378-40F6-89F3-CFDA06E6323BQ28834484-8EBD14E9-F32D-41F6-BC3F-A4E88B024A04Q30358389-0B02105E-04A6-4E2F-BE34-F3BAC6560005Q30398565-69D918F8-2298-4AFA-918E-DF946A19F8C9Q30581315-A7135883-5C58-49EF-AD2A-FD9C9EEECB27Q31143548-3B395076-6D53-4F93-8098-D4F196C1E1DDQ33792739-3C3E52F4-03AB-4B9D-99AF-5FE4FA13BEA0Q33805225-2B1A6CC2-7618-435A-B2D3-736B614B2AEBQ33915894-B6709ED5-3DC4-4A7F-9AC2-C21F412804BBQ34164962-94F6DF86-DB7D-4358-AF6D-228FE61FEF1AQ34299137-232FD3E6-A8F1-4001-9AD4-8AF17B473C77Q34327703-EC697826-365C-4784-9D30-56BCD7CF41ABQ35245970-AAE3264A-1586-4056-9EE4-00E17D18A502Q35983960-67BF6C6D-5E35-4A26-B82A-B8CAA71985A6Q37263372-BCABABB0-B1A4-4877-9D3A-78253719DEF7Q37269801-531A2135-8136-4C6D-96E5-C7A4AA33F2EBQ37274934-17B01694-73C1-4573-BBAD-10C48EDB6FCFQ37432620-A731AFC7-CA82-491C-96F2-C8B54CE85C5FQ37724010-02F8543D-002D-42D9-BAA5-EB9B37B3C4A8Q37981543-28867F6E-B173-4F72-BA70-8A03C4892D0DQ38052406-BB1FF529-2768-4F05-9F06-91A2D6543EDFQ38199383-42F42C54-1DBB-4986-804E-0804C4F36072Q38207472-1112E44B-90B0-47E0-8210-8DCE13FB96F2Q38289334-CC56D04F-BD9F-4B3B-8DEE-0A23B852CC0BQ38690083-20856354-F684-44AE-8141-968560261B2DQ38710506-BF736CA3-AD3B-4A46-BAF0-002D484BDBA1Q38760811-2B312998-96DB-4D1E-8F98-60A44D8B46A7Q38775808-9C62EA09-2F16-46F2-AD62-AB15AD5C0A30Q38814887-23389D5C-7869-47EA-9940-A46A613743E6Q38957599-6233BB46-1333-42A4-8148-7201D01A47F7Q39000218-6369B661-EDE2-4A11-A096-4EBC770C57BBQ39010752-117C4D49-B76C-4B04-8D69-8BFC0F609622Q39013723-F2F8AE2A-BF0B-46A6-8737-AAC93134AE1DQ39026748-D9CAA859-D1EF-47F4-AA70-06D11FADF763Q39031995-DD88C5F0-C7A2-49D9-9AD4-B49533718C1BQ39036280-713E83F7-7D7C-4A1F-8FE6-BC13E17CCFEBQ39052398-7E7DDB14-0635-4D1A-85AB-08D915B7F67BQ39121561-B3F128C3-1349-4062-B979-348C037B5343
P2860
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.
@ast
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.
@en
type
label
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.
@ast
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.
@en
prefLabel
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.
@ast
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.
@en
P2860
P356
P1433
P1476
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs
@en
P2093
Alberta Bergamo
P2860
P304
P356
10.1039/C0DT01816C
P407
P50
P577
2011-06-01T00:00:00Z